| |
| |
|
| Insider
Information: |
Brockstedt Dirk G. |
| Relationship: |
|
| City: |
Berkeley |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
152,423 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$5,148,725 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
152,423 |
|
|
| Total
Value |
$5,148,725 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -107.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Chinook Therapeutics Inc |
KDNY |
EVP of Research and Dev. |
2017-12-29 |
124,603 |
2015-11-16 |
0 |
Premium* |
|
|
Rapt Therapeutics, Inc. |
RAPT |
|
2024-01-05 |
27,820 |
2020-01-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
86 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-08-07 |
4 |
OE |
$0.52 |
$5,200 |
D/D |
10,000 |
59,300 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-09-01 |
4 |
AS |
$11.69 |
$116,948 |
D/D |
(10,000) |
49,300 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-09-01 |
4 |
OE |
$0.52 |
$5,200 |
D/D |
10,000 |
59,300 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
27,975 |
77,275 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-09-13 |
4 |
S |
$10.99 |
$39,076 |
D/D |
(3,557) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-10-02 |
4 |
AS |
$10.59 |
$105,870 |
D/D |
(10,000) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-10-02 |
4 |
OE |
$0.52 |
$5,200 |
D/D |
10,000 |
83,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-06 |
4 |
AS |
$8.04 |
$33,132 |
D/D |
(4,123) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-06 |
4 |
OE |
$0.52 |
$2,144 |
D/D |
4,123 |
77,841 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-10 |
4 |
AS |
$8.01 |
$14,544 |
D/D |
(1,815) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-10 |
4 |
OE |
$0.52 |
$944 |
D/D |
1,815 |
75,533 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-13 |
4 |
AS |
$8.00 |
$32,496 |
D/D |
(4,062) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-11-13 |
4 |
OE |
$0.52 |
$2,112 |
D/D |
4,062 |
77,780 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-12-01 |
4 |
OE |
$0.52 |
$5,200 |
D/D |
10,000 |
83,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-12-01 |
4 |
AS |
$9.40 |
$93,998 |
D/D |
(10,000) |
73,718 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-12-15 |
4 |
S |
$8.11 |
$529,187 |
D/D |
(65,223) |
72,603 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-12-15 |
4 |
OE |
$1.45 |
$92,957 |
D/D |
64,108 |
137,826 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
EVP of Research and Dev. |
• – – |
2017-12-29 |
4 |
OE |
$1.45 |
$75,400 |
D/D |
52,000 |
124,603 |
0 |
- |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
0 |
- |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-05-15 |
4 |
OE |
$6.18 |
$61,040 |
D/D |
9,877 |
20,133 |
0 |
- |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-05-15 |
4 |
AS |
$15.00 |
$148,155 |
D/D |
(9,877) |
10,256 |
0 |
% |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-08-17 |
4 |
AS |
$23.13 |
$236,328 |
D/D |
(9,877) |
10,256 |
0 |
% |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-08-17 |
4 |
OE |
$6.18 |
$61,040 |
D/D |
9,877 |
20,133 |
0 |
- |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-11-02 |
4 |
AS |
$28.06 |
$53,595 |
D/D |
(1,910) |
10,256 |
0 |
% |
|
| RAPT |
Rapt Therapeutics, Inc. |
Chief Scientific Officer |
• – – |
2020-11-16 |
4 |
OE |
$6.18 |
$61,821 |
D/D |
9,877 |
20,133 |
0 |
- |
|
86 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
